Place order

Novo Nordisk Compound Sharing

Your information

Please insert the requested information below to ensure that we have the correct information to allow for a compound shipment to arrive at your lab. The information you enter will also be used for the Novo Nordisk Compound Sharing agreement (containing the information provided in the order form, the compound request and the terms and conditions described below), which will be sent to you by e-mail if your request is approved.

Institution / company details

Institution / company name*

This field is required

Department name*

This field is required

Department zip code*

This field is required

Country*

This field is required

Shipping may require an import permit provided by you. Please note that we may be prevented from shipping to your country.

CVR number/tax ID*

This field is required

Street and number*

This field is required

Department city*

This field is required

State*

Personal information

First name*

This field is required

Position*

This field is required

Phone number*

This field is required Invalid phone number

Are you the receiver of the shipment?*

Yes

No

Last name*

This field is required

E-mail address*

This field is required Please provide a valid e-mail

E-mail address of receiver*

This field is required Please provide a valid e-mail

Phone number of reciever*

This field is required

How did you hear about the website?*

This field is required

Other source*

This field is required

Additional information

Will your study include in vivo experiments?*

Yes

No

Will your study include use of human biosamples?*

Yes

No

TERMS AND CONDITIONS

These are the terms and conditions for Novo Nordisk A/S (“Novo”) providing you the selected Compounds. By accepting these terms and conditions, Novo and you are entering into an agreement covering the transfer and use of the Compounds (the “Agreement”), subject to you receiving final email notification that Novo has accepted your request.

Novo will ship the Compounds to you free of charge, however, you are responsible for any customs or VAT duties applicable in your country.

The Compounds provided to you under this Agreement will be used solely by you and your team for the Study Purpose (as described in your Compound request form). Except to the extent necessary to carry out the Study Purpose, you shall not analyse, modify, synthesise or create derivatives of any of the Compounds provided under this Agreement. You agree not to sell or distribute the Compounds to any third party.

You agree to use the Compounds in compliance with any and all applicable laws and regulations. You shall not administer the Compounds to humans under any circumstances.

You are free to publish the data and study results obtained from the use of the Compounds. You shall acknowledge Novo and the Novo Nordisk Compound Sharing in any publication publishing such data and study results. Please use the following format:

“NNCXXXX-XXXX was provided by Novo Nordisk Compound Sharing”

This Agreement shall not be interpreted as granting you any right or license under any intellectual property, now or hereafter owned or controlled by Novo. Any intellectual property generated by you carrying out the Study Purpose will belong to you.

This Agreement will become effective on the date you receive final email notification that Novo has accepted your request and will remain effective until the completion of the study. Novo may terminate this Agreement in case of your material breach of the Agreement. All terms that are intended to survive termination, will survive, including but not limited to the Compounds only being used for the Study Purpose and you acknowledging Novo and the Novo Nordisk Compound Sharing in any publication.

You cannot assign this Agreement to a third party without the prior written consent of Novo. Novo will have the right at any time to assign or transfer any or all of its rights and obligations under this Agreement to any of its affiliates.

You acknowledge that the Compounds are provided “as is” and without any representation or warranty, express or implied, as to the accuracy or completeness of the Compounds, including, without limitation, any implied warranty of merchantability or fitness for a particular purpose, or any warranty that the use of the Compounds will not infringe or violate any patent or other proprietary rights of any third party. Acceptance of receipt of the Compounds will constitute acceptance by you of liability for any damages or injuries resulting from your use of the Compounds.

You and Novo each hereby agrees to hold harmless and indemnify the other party against any and all losses and/or liabilities resulting from such party’s breach of this Agreement and/or unauthorised use and/or disclosure of the Compounds.

THIS AGREEMENT SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF DENMARK TO THE EXCLUSION OF ANY RULE THAT WOULD REFER THE SUBJECT MATTER TO ANOTHER FORUM. YOU AND NOVO AGREE TO THE EXCLUSIVE JURISDICTION OF THE DANISH COURTS.

NOVO NORDISK PRINCIPLES ON THE USE OF ANIMALS

When performing in vivo experiments, you must adhere to the following principles:

- All activities involving animals must be conducted strictly in accordance with present legislation.

- Animals will be used only where no available and acceptable alternatives exist.

- Alternatives to animal experiments must be used whenever possible.

- Transgenic animals may be used for testing and experiments when this model is justified.

- Animals bred specifically for experimental purposes must be used unless special conditions are in evidence.

- Housing, husbandry and transportation of animals must as a minimum comply with internationally approved standards.

- Housing conditions must take into consideration the special needs for the animal species in question.

- Housing, husbandry and care of animals must be undertaken by personnel having received adequate and relevant education. The level of education must be documented.

- Health control should be supervised by a veterinary officer experienced in regard to laboratory animals.

- Transportation of animals must be as lenient as possible, taking into consideration the special needs for the animal species in question.

- All precautions must be taken to reduce suffering and distress.

- Procedures for monitoring and evaluation of the well-being of the animals as well as treatment must be implemented.

If you are receiving NNC0100-0454 (insulin degludec), NNC0090-1170 (liraglutide) or NNC0113-0217 (semaglutide) for performing in vivo experiments, there is a process for handling and reporting of potentially serious and unexpected adverse findings which all personnel supporting the studies must follow.

This is to assure compliance with regulatory requirements. You will receive a list of ‘expected adverse findings’ which should not be reported. If there is a finding during your studies that is determined as potentially serious and unexpected, an email must immediately be sent to compoundsharing@novonordisk.com with a description of the finding.